Temporal regulation of BMP signaling in patterning the tracheal cartilage and pharmacological approaches to prevent tracheomalacia (DivSupp)

NIH RePORTER · NIH · R01 · $63,816 · view on reporter.nih.gov ↗

Abstract

ABSTRACT Tracheomalacia is the most common structural abnormality in the lower airway. The estimated incidence in children ranges from 1 in 1,500 to 1 in 2,500. Tracheomalacia is very often associated with congenital syndromic disorders and congenital tracheomalacia associated with impaired cartilage integrity often represents the ones with severe symptoms, less regression percentage and higher mortality rate. Currently, surgical intervention is the only option, which requires disproportionately high allocation of health care resources. The lack of knowledge on the tracheal cartilage development and the pathophysiological mechanisms lead to impaired tracheal cartilage integrity prevent searching for alternative interventions for congenital tracheomalacia. BMP signaling has been demonstrated as a critical growth factor necessary for chondrogenesis and cartilage development, however, how BMP signaling is regulated during tracheal cartilage development has not been investigated. EvC syndrome (OMIM 225500) is an autosomal recessive chondrodysplasia. Neonatal death subsequent to airway collapse has been documented in patients with EvC syndrome. Our preliminary studies using Evc2 mutant mice uncover the potential novel mechanisms on the regulated BMP signaling both in foregut mesenchyme and in tracheal mesenchyme. We have demonstrated that well-orchestrated BMP signaling in foregut and tracheal mesenchyme is necessary for tracheal cartilage developing into correct shape. Our preliminary studies lead us hypothesize that: Hedgehog-BMP axis at foregut mesenchyme determines the BMP signaling levels in tracheal mesenchyme and the subsequent chondrogenesis; after trachea and esophagus separation, extracellularly stored BMP ligands play a critical role in inducing BMP signaling in tracheal mesenchyme for subsequent chondrogenesis; and that administration of FK506 has the potential to correct the congenital defective tracheal cartilage in Evc2 mutant mice. During 2 years of the funding period of the parent grant, we have made substantial progresses on the Aim 1 and Aim 3. We are currently putting more efforts towards Aim 2 experiments, which require intensive mouse breeding and subsequent tissue isolation and molecular assessments. Addition of Mr. Sher Khehra will further accelerate our team efforts to propel our progress and enhance the diversity of our interdisciplinary team, while providing his meaningful career development opportunity.

Key facts

NIH application ID
11045208
Project number
3R01HL162939-03S1
Recipient
UNIVERSITY OF MICHIGAN AT ANN ARBOR
Principal Investigator
Yuji MISHINA
Activity code
R01
Funding institute
NIH
Fiscal year
2024
Award amount
$63,816
Award type
3
Project period
2022-04-01 → 2025-02-28